Skip to main content
. 2019 Mar 18;91(7):1250–1262. doi: 10.1002/jmv.25441

Table 4.

Clinical and demographic data of patients with replicant and persistent HAdV detected in palatine tonsils

Disease patients group Control patients group
Replicant HAdV Persistent HAdV Replicant HAdV Persistent HAdV
Patients 4 (8.2%) 45 (91.8%) 0 (0.0%) 2 (100.0%)
Males 2 (50.0%) 21 (42.3%) 1 (50.0%)
Age (median of years) 4.0 5.0 3.0
Viral coinfection 3 (75.0%) 30 (66.6%) 0 (0.0%)
Viral load (median copies/g) 9.56 × 105 4.50 × 104 1.8 × 104
High viral load (>106)* 2 (50.0%) 5 (11.1%) 0 (0.0%)
Detection in several sites 4 (100.0%) 37 (82.2%) 2 (100%)
Spreading of HAdV in NPS 3 (75.0%) 20 (44.4%)
Recurrent tonsillitis 3 (75.0%) 26 (57.7%)
Tonsillar hypertrophy 4 (100.0%) 37 (82.2%)
Sleep apnea 4 (100.0%) 25 (55.5%)
Otitis media with effusion 0 (0.0%) 8 (17.7%)
Allergy 1 (25.0%) 13 (28.8%)

Abbreviations: HAdV, human adenovirus; NPS, nasopharyngeal secretion.

*

P < 0.05.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.